Abstract

The success of marrow transplantation is heavily dependent on the transfusion of blood products and is a situation which provides many opportunities for research in transfusion immunology. In Project IX we have described our research proposals for problems of platelet alloimmunization. In Project III we describe our proposals for the utilization of blood products screened for antibody to cytomegalovirus (CMV) as well as an evaluation of leukocyte-depleted blood products for the prevention of CMV. In this core section we are concerned with mechanisms for deriving research information from clinically necessary transfusion support and plasma modification procedures. We ask support only for key personnel for supervision and data entry where we cannot recover costs from charges but where the work is essential to carrying out the proposed research in individual program projects. These areas include establishing and maintaining data bases containing detailed descriptive information on all blood product transfusions and on the course and outcome of all ABO-incompatible transplants requiring plasma modification or marrow red cell depletion.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-13
Application #
3819940
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications